Pharming reports positive data from first investigator-initiated study of rhC1-Inhibitor (RUCONEST®) in Contrast-induced Nephropathy
Pharming Group N.V. announced positive results from a Phase II investigator-initiated study of RUCONEST® (recombinant human C1 esterase inhibitor, or “rhC1INH”) in a double-blind, placebo-controlled clinical trial in patients at risk of nephropathy resulting from contrast-enhanced examinations.
The overall assessment of the study also showed trends that patients undergoing more invasive interventions and procedures requiring higher volumes of contrast medium experienced a stronger benefit from the RUCONEST® treatment.
“Reaching a significant difference already in a small number of patients in this well-run exploratory trial gives a surprisingly clear positive signal in what could become a large new indication for RUCONEST®.”
- Bruno Giannetti - COO